Positive inotropes - A new horizon or still a dead end?

Cardiovascular Drugs and Therapy

Volumn 15, Issue 5, 2001, Pages 375-377

  Remme, Willem J ^a  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; INOTROPIC AGENT; PHOSPHODIESTERASE INHIBITOR;

DISEASE ASSOCIATION; EDITORIAL; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART FAILURE; HEART RATE; HUMAN; HYPOTENSION; INOTROPISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; TACHYPHYLAXIS; TREATMENT PLANNING;

ATRIAL FIBRILLATION; CARDIOTONIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYPOTENSION;

EID: 0035700748     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1013309819680     Document Type: Editorial

References (10)

1. Guidelines for the diagnosis and treatment of chronic heart failure
2. Positive inotropic therapy: Dead end or new horizon?
3. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
4. +channel activators as positive inotropic agents for the treatment of heart failure
5. Phospholamban: A promising therapeutic target in heart failure?
6. Energetic stimulation of the heart
7. 2+sensitizers - Update 2001
8. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
9. Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels
10. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure